Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1/2 12Phase 3 9Phase 1 8Phase 2/3 3Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Hormone Receptor Positive HER-2 Negative Breast Cancer 1CCND1 Gene Amplification 1Breast Neoplasms 1

Interventions

Paclitaxel 9Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Cisplatin 8Carboplatin 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Radiotherapy, Intensity-Modulated 6Nivolumab 6Leucovorin 6Filgrastim 6Drug Therapy 6Doxorubicin 6Radiotherapy 5Oxaliplatin 5Fluorouracil 5Docetaxel 5Bevacizumab 5pembrolizumab 4gallium 68 PSMA-11 4Taxes 4Sirolimus 4Rituximab 4Pemetrexed 4Melphalan 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Dexamethasone 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × palbociclib × Clear all
NCT04191499 2026-03-17

INAVO120

Hoffmann-La Roche

Phase 2/3 Active not recruiting
325 enrolled 14 charts 1 FDA
Breast

Breast Neoplasms

NCT02692755 2021-09-28

PALINA

Georgetown University

Phase 2/3 Completed
35 enrolled 12 charts
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

NCT02785939 2021-05-27

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2/3 Completed
53 enrolled 15 charts

CCND1 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡